CD161 CRISPR/Cas9 KO Plasmid (h): sc-405895
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD161 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD161 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD161 Antibody (B199.2): sc-58963
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD161 CRISPR/Cas9 KO Plasmid (h) | sc-405895 | 20 µg | $397.00 |
Overview
KLRB1 encodes CD161 (KLRB1), a C-type lectin-like receptor prominently expressed on subsets of NK cells and T cells, including mucosal-associated invariant T (MAIT) cells and Th17-like populations. CD161 participates in immunoregulatory signaling and modulation of cytotoxicity and cytokine output through receptor-mediated pathways that shape innate and adaptive immune responses. Altered KLRB1/CD161 expression is associated with immune activation states and inflammatory contexts, and it is frequently used to phenotype functionally distinct lymphocyte subsets in studies of infection, autoimmunity, and tumor immunology. As a surface receptor linked to effector programs such as IL-17–skewed responses and tissue homing, CD161 provides a tractable entry point for dissecting lymphocyte differentiation and function.
CD161 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KLRB1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KLRB1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KLRB1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD161 protein expression.
This CRISPR knockout system enables efficient generation of KLRB1-deficient cell models for investigation of CD161 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KLRB1 exon(s) critical for CD161 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KLRB1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD161 CRISPR/Cas9 KO Plasmid (h) and CD161 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KLRB1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD161 HDR Plasmid (h) and CD161 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KLRB1 homology arms to support homology-directed repair at defined KLRB1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.